Literature DB >> 17174721

IL-1beta induces alkaline phosphatase in human phagocytes.

Lakshmi N Shanmugham1, Claudia Petrarca, Maria L Castellani, Isaia Symeonidou, Stavros Frydas, Jacopo Vecchiet, Katia Falasca, Stefano Tetè, Pio Conti, Vincenzo Salini.   

Abstract

BACKGROUND: Alkaline phosphatase (ALPase) is found in blood plasma or serum and leukocytes and regulates intercellular processes, maintaining phosphoryl metabolites in a steady state, as well as synthesizing and hydrolyzing phosphate esters on membranes. ALPase supervises the active transport of inorganic phosphates, fats, proteins, carbohydrates and the sodium/potassium pump mechanisms. The formed elements of blood such as polymorphonuclear (PMNs) leucocytes, macrophages (MP) and some lymphocytes are high in ALPase concentrations.
METHODS: In this study we have tested whether the interleukin-1 receptor antagonist (IL-lra) could influence ALPase generation in IL-1beta or lipopolysaccharide (LPS)-stimulated neutrophils and MP. Human neutrophils were isolated from heparin-anticoagulated blood drawn from healthy individuals by centrifugation in a two-step gradient, Ficoll-Hypaque. ALPase activity was assessed spectrophotometrically in test tubes containing isolated neutrophils and adherence PBMCs treated with LPS, IL-1beta and IL-1ra, alone or in combination.
RESULTS: IL-lbeta or LPS enhanced ALPase in both PMNs and MP, whereas IL-1ra could not inhibit ALPase activity. We performed time course experiments at 0 min, 5 min, 1 h, 24 h, and 43 h (LPS 20 microg/mL, IL-1beta 10 ng/mL). No significant increase in ALPase activity was seen until 1 h; however, there was a rapid rise over the next few hours. In another set of experiments using IL-1ra (500 ng/mL), there was no difference between treated cells and control cells. The combination of IL-1beta plus IL-1ra did not reduce the ability of IL-1beta to induce ALPase activity.
CONCLUSIONS: These data suggest that IL-1beta stimulates ALPase through other mechanisms than the release of arachidonic acid products, which are inhibited by IL-lra.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17174721     DOI: 10.1016/j.arcmed.2006.05.016

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  6 in total

Review 1.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

Review 2.  Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Giuseppe Cianciolo; Simona Barbuto; Gaetano La Manna; Lorenzo Gasperoni; Giovanni Tripepi; Mario Plebani; Maria Fusaro; Per Magnusson
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

3.  Human alkaline phosphatase dephosphorylates microbial products and is elevated in preterm neonates with a history of late-onset sepsis.

Authors:  Matthew Pettengill; Juan D Matute; Megan Tresenriter; Julie Hibbert; David Burgner; Peter Richmond; José Luis Millán; Al Ozonoff; Tobias Strunk; Andrew Currie; Ofer Levy
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

4.  Prognostic impact of preoperative serum alkaline phosphatase level on a composite of morbidity and mortality after thoracic endovascular aortic repair: A retrospective study.

Authors:  Sung Yeon Ham; Sang Beom Nam; Dong Woo Han; Ann Hee You; Won Sik Lim; Young Song
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 5.  Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

Authors:  Mathias Haarhaus; Dean Gilham; Ewelina Kulikowski; Per Magnusson; Kamyar Kalantar-Zadeh
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-01       Impact factor: 3.416

6.  Prognostic Significance of Preoperative Albumin to Alkaline Phosphatase Ratio in Patients with Glioblastoma.

Authors:  Junhong Li; Mingrong Zuo; Xingwang Zhou; Yufan Xiang; Shuxin Zhang; Wentao Feng; Yanhui Liu
Journal:  J Cancer       Date:  2021-08-13       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.